Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Musculoskeletal  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Acute Myeloid Leukemia Clinical Trials

A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (160) clinical trials

MSC and HSC Coinfusion in Mismatched Minitransplants

The present project aims at evaluating the capacity of MSC to improve one-year overall survival of patients transplanted with HLA-mismatched PBSC from related or unrelated donors after non-myeloablative conditioning. Co-infusion of MSC has been shown to facilitate engraftment of hematopoietic stem cell (HSC) in an immunodeficient mouse model. In addition, ...

Phase

Higher or Lower Dose Cladribine Cytarabine and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

PRIMARY OBJECTIVES: I. To evaluate the feasibility of randomizing medically less fit adults with newly diagnosed acute myeloid leukemia (AML) or analogous myeloid neoplasms to either intensive or non-intensive induction and post remission chemotherapy. SECONDARY OBJECTIVES: I. To evaluate the attitude of patients and physicians toward randomization and explore reasons ...

Phase

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

PRIMARY OBJECTIVES: I. To determine the clinical activity of kinase inhibitors using pre-clinical (in-vitro) activity to select individual therapy. SECONDARY OBJECTIVES: I. To evaluate overall objective response rates (complete response plus partial response). II. Determine overall survival (OS) and progression-free survival (PFS). III. Any changes in transfusion requirements. TERTIARY OBJECTIVES: ...

Phase

Treosulfan Fludarabine Phosphate and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

PRIMARY OBJECTIVES: I. Graft failure/rejection and secondary graft failure. II. Day -200 non-relapse mortality. SECONDARY OBJECTIVES: I. Platelet engraftment by six months. II. Grade II-IV and III-IV acute graft-versus-host disease (GVHD) at day 100 and one year. III. Chronic GVHD. IV. Clinically significant infections. V. Overall survival. VI. Relapse or ...

Phase

Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

PRIMARY OBJECTIVES: I. To test the association between biochemical response and clinical response. SECONDARY OBJECTIVES: I. To estimate complete response rate of sirolimus MEC in patients with high risk AML. II. To estimate progression free survival in this patient population. III. To collect further information on the safety, tolerability, and ...

Phase

Umbilical Cord Blood Transplant Cyclophosphamide Fludarabine Phosphate and Total-Body Irradiation in Treating Patients With Hematologic Disease

PRIMARY OBJECTIVES: I. To determine the one year survival of patients undergoing umbilical cord blood transplantation (UCBT) after a myeloablative preparative regimen consisting of cyclophosphamide (CY), fludarabine phosphate (fludarabine [FLU]), and fractionated total body irradiation (TBI). SECONDARY OBJECTIVES: I. Incidence of transplant-related mortality (TRM) at 6 months. II. Chimerism at ...

Phase

Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse

Study Drug Administration: Each study cycle is 28 days. If you are found to be eligible to take part in this study, you will receive nivolumab by vein over about 1 hour on Days 1 and 15 of each cycle. After Cycle 6, you may receive nivolumab 1 time each ...

Phase

Chemotherapy Total Body Irradiation and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

PRIMARY OBJECTIVES: I. To determine the cumulative incidence of extensive chronic graft versus host disease (GVHD) at 1 year after transplantation utilizing the novel conditioning/GVHD prophylactic regimen for patients undergoing allogeneic hematopoietic cell transplantation, in patients who do not progress before day 100. SECONDARY OBJECTIVES: I. To evaluate clinical response, ...

Phase

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

PRIMARY OBJECTIVE: To compare the rate of disease-free survival (DFS) at 1 year post hematopoietic stem cell transplant (HSCT) in patients undergoing HSCT treated on this successor Thomas Jefferson University (TJU) 2 Step reduced intensity conditioning (RIC) haploidentical regimen and compare it with that of the initial 2 Step RIC ...

Phase

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Study Drug Administration: If you are eligible to take part in this study, you will receive 1 or 2 cycles of induction therapy followed by up to 17 cycles of consolidation therapy. Each study cycle is 4 weeks. Induction Cycles: On Days 1-5, you will receive cladribine by vein over ...

Phase